Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 re

The global pediatric diabetes therapeutic market is set to reach USD 1,633.8 million in 2024. Projections indicate that the sector is anticipated to elevate to USD 2,612.4 million by 2034. The industry stood at USD 1,540.2 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 6.1% in 2024. Demand for pediatric diabetes therapeutics is slated to surge at a 4.8% CAGR.

Attributes	Description
Estimated Global Pediatric Diabetes Therapeutic Market Size (2024E)	USD 1,633.8 million
Projected Global Pediatric Diabetes Therapeutic Market Value (2034F)	USD 2,612.4 million
Value-based CAGR (2024 to 2034)	4.8%

Country-wise Insights

Countries	CAGR 2024 to 2034
United States	5.4%
China	5.3%
Germany	4.8%
United Kingdom	4.4%
India	4.5%

Category-wise Insights

Segment	Type 1 (Diabetes)
Value Share (2024)	56.2%

Segment	Insulin Therapy (Therapy)
Value Share (2024)	57.2%

The global obesity-diabetes drugs market is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.

Attributes	Description
Estimated Global Obesity-Diabetes Drugs Market Size (2024E)	USD 56,739.0 million
Projected Global Obesity-Diabetes Drugs Market Value (2034F)	USD 97,567.4 million
Value-based CAGR (2024 to 2034)	5.6%

Country-wise Insights

Countries	CAGR 2024 to 2034
The United States	4.7%
China	5.7%
Germany	3.8%
The United Kingdom	4.0%
India	6.4%

Category-Wise Insights

Segment	Drug Therapy (Therapy Type)
Value Share (2024)	55.9%

Segment	Institutional Sales (Sale Channel)
Value Share (2024)	39.7%

The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The Indonesia Diabetes Drugs Market Report is Segmented by Drug Class (Oral Anti-Diabetics, Insulins, Combination Drugs and Non-Insulin Injectable Drugs), Diabetes Type (Type-1 Diabetes and Type-2 Diabetes), and Distribution Channel (Hospital Pharmacies, Retail Chain Pharmacies and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%

Type 1 Diabetes Market valued at USD 16.97 Bn in 2025, is anticipated to reaching USD 26.22 Bn by 2032, with a steady annual growth rate of 6.4%.

Diabetes Devices And Drugs Market valued at USD 191.66 billion in 2025, is anticipated USD 373.49 billion by 2032, with a steady annual growth rate of 10.0%.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

Planned monitoring requirements combined with insulin requirements for diabetic pets among dogs and cats create a market need for specialized care devices. Pixel GPS medicine forecasts the market to achieve USD 2,594 million in 2025 but predicts an increase to USD 4,645.5 million by 2035 at a compound annual growth rate (CAGR) of 6%.

Metric	Value
Industry Size (2025E)	USD 2,594 million
Industry Value (2035F)	USD 4,645.5 million
CAGR (2025 to 2035)	6%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
USA	6.4%

Country	CAGR (2025 to 2035)
UK	5.8%

Region	CAGR (2025 to 2035)
European Union	6.0%

Country	CAGR (2025 to 2035)
Japan	5.6%

Country	CAGR (2025 to 2035)
South Korea	6.2%

Segmentation Outlook - Pet Diabetes Care Devices Market

Device Type	Market Share (2025)
Glucose Monitoring Devices	57.9%

End-User Segment	Market Share (2025)
Veterinary Clinics	46.4%

Competitive Outlook

Company Name	Estimated Market Share (%)
Zoetis Inc.	20-24%
Trividia Health, Inc. (PetTest)	15-19%
Merck Animal Health	12-16%
UltiMed, Inc.	8-12%
i-SENS, Inc.	5-9%
Other Companies (combined)	30-40%

The global gestational diabetes market is projected to exceed USD 19,811.32 Mn by 2032, advancing from USD 9,870.25 Mn in 2024, with an estimated growth of USD 10,592.57 Mn in 2025, at a CAGR of 9.1% from 2025 to 2032.

The type 1 diabetes market size was valued at USD 7.90 Billion in 2024, driven by the increasing prevalence of diabetes across the 7 major markets. The market size is anticipated to grow at a CAGR of 6.80% during the forecast period of 2025-2034 to achieve a value of USD 15.25 Billion by 2034.

The North America Diabetes Drugs Market Report is Segmented by Drug Class (Insulins [Biosimilar Insulin and More], Non-Insulin Injectable, Oral Anti-Diabetic and Combination Drugs), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Drug Origin (Branded and Generic/Biosimilar), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The China diabetes market size reached a value of almost USD 4.73 Billion in the year 2024. The market is further expected to grow at a CAGR of 9.50% between 2025 and 2034 to reach a value of almost USD 11.72 Billion by 2034.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

Insulin Analog 1 Diabetes Market size is set to expand from $ 5.96 Billion in 2023 to $ 8.53 Billion by 2032, a CAGR of around 4.2% from 2024 to 2032.

As per Cognitive Market Research's latest published report, the Global Diabetes nutrition market size was USD 5,567.2 million in 2022. Diabetes nutrition Industry's Compound Annual Growth Rate will be 6.9% from 2023 to 2030. Factors Impacting on Diabetes Nutrition Market

The increasing prevalence of diabetes due to unhealthy lifestyles among people is forecasted to dominate the global diabetes nutrition market. In addition, increased product launches by major market players coupled with the easy availability of diabetic and dietary food are forecasted to dominate the global market. Furthermore, the development of innovative diabetic nutritional products will provide an opportunity for the global market. However, a lack of awareness regarding nutritional deficiency among the diabetic population may hamper the global market growth. What is Diabetes Nutrition?

Diabetic nutrition is dietary products that have low carbohydrate and sugar content and help in controlling glucose levels in the blood. Diabetes is a disease defined as high blood sugar levels resulting from insufficient insulin or a lack of cell response to the insulin produced by the body. Furthermore, diabetes damages various other body parts such as the nerves, kidneys, brain, eyes, and feet. Food products such as whole grains, millet baked sweet potato, brown rice, quinoa, and oatmeal are considered healthy foods for people who have diabetes.

Diabetes Care Service Market Outlook

The global diabetes care service market size is projected to witness significant growth, expanding from USD 25.8 billion in 2023 to USD 45.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. Key growth factors driving this market include the rising prevalence of diabetes, increasing awareness about diabetes management, and technological advancements in diabetes care services.

The rising prevalence of diabetes across the globe is a major growth factor for the diabetes care service market. According to the International Diabetes Federation, the number of adults living with diabetes was approximately 463 million in 2019 and is expected to rise to 700 million by 2045. This alarming increase necessitates efficient diabetes care services, including diagnostic, treatment, and consultation services, to manage this chronic condition effectively. Additionally, lifestyle changes, increased consumption of unhealthy food, and a rise in obesity rates contribute to the growing number of diabetes cases, further driving the demand for comprehensive diabetes care services.

Technological advancements in diabetes care services are revolutionizing the market. Innovations such as continuous glucose monitoring systems, insulin pumps, and telemedicine services have significantly improved diabetes management. These technologies provide real-time data, enabling better glucose control and reducing the risk of complications. Moreover, the integration of artificial intelligence and machine learning in diabetes care provides personalized treatment plans, enhancing patient outcomes. The adoption of these advanced technologies by healthcare providers and patients is a critical factor propelling the growth of the diabetes care service market.

Increasing awareness about diabetes management and the importance of early diagnosis is also driving market growth. Governments and health organizations worldwide are implementing various programs and campaigns to educate people about diabetes prevention and management. These initiatives aim to reduce the incidence of diabetes-related complications and improve the quality of life for those affected by the condition. Additionally, healthcare providers are emphasizing the importance of regular check-ups and screenings, leading to a higher demand for diabetes care services. The growing emphasis on preventive healthcare practices is expected to further boost market growth.

The regional outlook for the diabetes care service market shows significant growth potential in various regions. North America dominates the market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and favorable government initiatives. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to the increasing diabetic population, rising healthcare expenditure, and growing awareness about diabetes management. Europe also holds a substantial market share, attributed to the presence of well-established healthcare systems and supportive government policies. The Middle East & Africa and Latin America regions are gradually emerging as potential markets, driven by improving healthcare infrastructure and rising awareness about diabetes care.

Service Type Analysis

The diabetes care service market can be segmented by service type into Consultation Services, Diagnostic Services, Treatment Services, Education and Training Services, and Others. Consultation services play a pivotal role in diabetes management, as they provide personalized care plans, lifestyle modification advice, and regular monitoring. These services are essential for preventing complications and ensuring optimal health outcomes for diabetic patients. The increasing patient awareness about the importance of regular consultations and the growing number of healthcare providers offering these services are driving the segment's growth.

Diagnostic services are another critical component of the diabetes care service market. These services include blood glucose testing, HbA1c testing, urine analysis, and other diagnostic procedures essential for early detection and ongoing monitoring of diabetes. The rising prevalence of diabetes and the growing emphasis on early diagnosis and regular monitoring are fueling the demand for diagnostic services. Technological advancements, such as point-of-care testing devices and continuous glucose monitoring systems, are further enhancing the efficiency and accuracy of these services, contributing to market growth.

Treatment services encompas

Type 2 Diabetes Market Size reached US$ 61.50 billion in 2024 and is expected to reach US$ 124.26 billion by 2033

Diabetes Drug Market will reach USD 163.79 billion by 2034, expanding at a CAGR of 7.0 %.